A New Drug Application (NDA) in South Korea requires documentation including preclinical and clinical trial data, manufacturing process details, safety and efficacy reports, pharmacological studies, and quality control information. Applicants must also provide Good Manufacturing Practice (GMP) certification and comply with Ministry of Food and Drug Safety (MFDS) regulatory guidelines for review and approval.
